Oncoinvent Achieves 50% Phase 2 Enrollment for Radspherin in Ovarian Cancer Trial

Oncoinvent announced on June 18, 2026, that it has reached 50% patient enrollment in its Phase 2 RAD-201 clinical trial for Radspherin. The novel alpha-emitting radioactive microsphere suspension is being evaluated for treating peritoneal carcinomatosis in ovarian cancer patients. The news led to an increase in the company's stock. Radspherin is designed for intracavitary delivery to target residual cancer cells following surgery. The ongoing RAD-201 study aims to assess the safety and efficacy of Radspherin in patients with advanced ovarian cancer who have peritoneal carcinomatosis. This milestone follows promising safety and preliminary efficacy data reported from the company's Phase 1 trial. The advancement in Phase 2 enrollment signifies progress in developing new therapeutic options for this challenging cancer indication.